RDHLNasdaqPharmaceutical Preparations
RedHill Biopharma Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 27, 2026
$0.50+0.02 (+4.39%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Sep 30, 2026 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Sep 5, 2025 | Before market open | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 17, 2023 | Before market open | – | – | – |
Press releases
Announcements RedHill Biopharma filed with the SEC
NCI Grant Awarded for Clinical Development of
EX-99.1 to Form 6-K
CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION
EX-99.2 to Form 6-K
Commercialization Rights to Ferring’s Rebyota ® and Clenpiq ®
EX-99.1 to Form 6-K
Talicia ® to Apotex for $18 Million Cash
EX-99.1 to Form 6-K
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION
EX-99.1 to Form 6-K
RedHill’s Talicia ® Secures $4 Million Strategic Investment
EX-99.1 to Form 6-K
CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION
EX-99.2 to Form 6-K
RedHill Biopharma Announces First Half 2024 Business Highlights
EX-99.1 to Form 6-K
CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION
EX-99.2 to Form 6-K
Holder of Ordinary Share Purchase Warrants
EX-99 to Form 6-K
CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION
EX-99.2 to Form 6-K
PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY
EX-99#2 to Form 6-K
PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY
EX-99#2 to Form 6-K
RedHill’s Opaganib Selected by the NIH Radiation and
EX-99.1 to Form 6-K
RedHill Announces Positive MHRA Meeting and Planned
EX-99.1 to Form 6-K
RedHill Biopharma Announces Positive FDA Meeting
EX-99.1 to Form 6-K
RedHill Biopharma and HealthCare Royalty Agree to
EX-99.1 to Form 6-K
RedHill Receives USPTO Notice of Allowance for a Patent
EX-99.1 to Form 6-K
RedHill Announces Publication of Positive Phase 2 Study
EX-99.1 to Form 6-K
RedHill’s Aemcolo ® Granted FDA QIDP 5-Year Exclusivity Extension
EX-99.1 to Form 6-K
CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION
EX-99 to Form 6-K
RedHill Biopharma Announces Q3/22 Results and
EX-99.1 to Form 6-K
RedHill Biopharma Announces Positive New Data with
EX-99.1 to Form 6-K
RedHill Accelerates Opaganib’s Nuclear Radiation Protection
EX-99.1 to Form 6-K
RedHill Biopharma Reaches Agreement in Principle with
EX-99.1 to Form 6-K
RedHill Biopharma Provides H1/22 Highlights and Q3/22
EX-99.1 to Form 6-K
CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION
EX-99.2 to Form 6-K
RedHill Presents New Talicia® Data Analyses at Obesity Week 2022
EX-99.1 to Form 6-K
RedHill Presents New Talicia® and Movantik® Data Analyses
EX-99.1 to Form 6-K